RadNet, Inc. (RDNT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects strong financial performance, with a $150 million contract value and a $140 million ARR run rate goal. Advanced imaging is growing, and new centers are ahead of schedule. The JV with Saint Alphonsus and the Gleamer acquisition show strategic growth. Improvements in working capital, low DSOs, and increased revenue guidance further contribute positively. Despite some unclear management responses, the overall sentiment, driven by strong financials, strategic initiatives, and positive guidance, suggests a positive stock price movement.
Key Financial Performance
Revenue Revenue increased 22.1% year-over-year despite being negatively impacted by an estimated $13 million due to severe weather conditions in January and February on the East Coast. This growth was driven by acquisitions, same-center advanced imaging procedure volume growth of 8.2%, and a 51.5% increase in digital health revenue.
Adjusted EBITDA Adjusted EBITDA increased 36.3% year-over-year, with a margin improvement of 115 basis points. This was achieved despite a $9 million negative impact from severe weather conditions. The improvement was driven by operational efficiencies, including the implementation of advanced imaging technologies and AI solutions.
Advanced Imaging Procedural Volume Advanced imaging procedural volume increased to 29.3% of total procedural volume, up from 26.9% in the previous year, a 235 basis point increase. This growth was attributed to industry trends and significant capital investments in advanced imaging equipment.
PET/CT Procedures PET/CT procedures increased 35.2% in aggregate and 14.7% on a same-center basis year-over-year. Growth was driven by studies for prostate cancer staging and detection of brain plaques related to Alzheimer's and dementia.
Digital Health Revenue Digital Health revenue increased by 51.5% year-over-year, driven by acquisitions of iCAD, CIMAR, and Gleamer, as well as the implementation of AI-powered solutions.
ARR (Annual Recurring Revenue) ARR for the Digital Health segment reached $97 million, representing a 95% year-over-year growth. This growth was supported by strong sales pipeline and commercial wins.
Cash Balance The company ended the quarter with a cash balance of $455 million, reflecting strong liquidity despite significant acquisition-related expenditures.
Net Debt to Adjusted EBITDA Ratio The net debt to adjusted EBITDA ratio was slightly under 2, reflecting prudent cash and debt management.
Imaging Center Segment Adjusted EBITDA Margin Adjusted EBITDA margin for the Imaging Center segment improved by 188 basis points year-over-year, driven by operational efficiencies and technology implementations.
Days Sales Outstanding (DSO) DSO reached a record low of 29.5 days, reflecting improvements in revenue cycle management and patient collections.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Advanced Imaging: Shift towards advanced imaging with 29.3% of procedural volume in Q1 2026 compared to 26.9% in Q1 2025. Investments in advanced imaging equipment have increased throughput and capacity.
TechLive Implementation: DeepHealth's remote scanning solution has improved MRI utilization by reducing exam room closure hours.
PET/CT Procedure Growth: 35.2% increase in PET/CT procedures, driven by studies for prostate cancer and brain plaques detection.
Digital Health Solutions: Integration of Gleamer SAS's AI solutions for musculoskeletal, breast, lung, and neurologic applications. Deployment of AI solutions like thyroid ultrasound AI and x-ray AI across RadNet centers.
Acquisitions in Southwest Florida and Indiana: Acquired Radiology Regional (13 centers) and Northwest Radiology (6 centers), expanding presence in these regions.
New Partnership in Idaho: Commenced partnership with Trinity Health Saint Alphonsus Health System, operating 5 centers and generating $30 million in annual revenue.
Revenue and EBITDA Growth: Q1 2026 revenue increased by 22.1% and adjusted EBITDA by 36.3% compared to Q1 2025.
Operational Efficiencies: Improved Imaging Center segment adjusted EBITDA margin by 188 basis points. Reduced ultrasound slot times by 33% using AI.
Cash and Liquidity: Ended Q1 2026 with $455 million in cash and a net debt to adjusted EBITDA ratio of under 2.
AI and Cloud-Native Technologies: Focused on transforming radiology workflow with AI-curated draft reports, dynamic case routing, and remote operations.
Digital Health ARR Growth: Achieved $97 million in annual recurring revenue (ARR) in Q1 2026, a 95% year-over-year growth.
Global Expansion: DeepHealth's external revenue reached 64% of total revenue, with an installed base of nearly 3,000 global customers.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Severe Weather Conditions: Severe weather conditions in January and February on the East Coast negatively impacted revenue by an estimated $13 million and adjusted EBITDA by $9 million.
Technologist Shortages: Industry-wide shortage of technologists poses challenges to maintaining high throughput and operational efficiency.
Integration of Acquisitions: The integration of recent acquisitions, including Radiology Regional, Northwest Radiology, and Gleamer SAS, requires significant effort and resources to streamline operations and deploy AI-powered solutions.
Regulatory Approvals: The need for continuous FDA clearances and CE marks for AI solutions creates dependency on regulatory processes, which could delay product launches or updates.
Financial Leverage: Increased financial leverage due to substantial cash spent on acquisitions, though managed prudently, could pose risks if free cash flow generation does not meet expectations.
Radiologist Burnout and Staffing Shortages: Radiologist burnout and stagnant supply of clinicians amidst rising imaging volumes create operational challenges and risks to maintaining quality care.
Dependence on AI and Technology: Heavy reliance on AI and cloud-native technologies for operational efficiency and scalability introduces risks related to technology failures, cybersecurity, and adoption rates.
Medicare Reimbursement Uncertainty: Uncertainty regarding Medicare reimbursement rates for 2027 could impact future financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Full Year Guidance: RadNet has raised its 2026 full year guidance for imaging center revenue, adjusted EBITDA, and free cash flow due to strong performance in March, April, and early May.
Revenue Growth: Revenue for the first quarter of 2026 increased by 22.1% compared to the previous year, driven by acquisitions, same-center advanced imaging procedure volume growth, and digital health revenue growth. Full-year revenue guidance has been increased by $30 million at both the low and high ends of the range.
Adjusted EBITDA: Adjusted EBITDA for the first quarter increased by 36.3% year-over-year. Full-year adjusted EBITDA guidance has been raised by $5 million at both the low and high ends of the range.
Free Cash Flow: Free cash flow guidance for 2026 has been increased by $7 million at both the low and high ends of the range.
Digital Health Segment: The Digital Health segment is on track to achieve $140 million in annual recurring revenue (ARR) by year-end 2026, with $97 million ARR achieved in Q1 2026. Full-year guidance for the segment remains unchanged at $135 million to $145 million in revenue and $10 million to $12 million in adjusted EBITDA.
Acquisitions and Integration: RadNet has completed significant acquisitions, including Radiology Regional in Florida, Northwest Radiology in Indiana, and Gleamer SAS in France. These acquisitions are expected to contribute to revenue growth and operational efficiency through the integration of AI-powered solutions.
AI and Technology Implementation: RadNet is deploying AI and cloud-native technologies to transform radiology workflows, improve efficiency, and address industry challenges such as radiologist burnout and imaging backlogs. Key initiatives include AI-curated draft reports, remote operations, and dynamic case routing.
Regulatory Approvals: RadNet expects to receive an additional 12 FDA clearances and 15 CE marks by the end of 2026, expanding its portfolio of AI and informatics solutions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key drivers of volume growth in the clinic business, and how sustainable are they?
A:The performance is driven by advanced imaging growth, with MRI volume at 10.1%, CT in mid-single digits, and PET/CT growth over 14%. Advanced imaging is profitable due to same-center performance and technological advancements. Management is optimistic about sustainability, citing strong performance in March, April, and early May.
Q:How should we think about the ramp and opportunity for upside from acquisitions and partnerships?
A:Acquisitions in Florida and Indiana contributed about $30 million in revenue and $2 million in EBITDA in Q1. Integration is ahead of schedule, and management expects these assets to meet their 2026 projections.
Q:What is the outlook for revenue growth post-2026, particularly in clinical AI and DeepHealth?
A:The commercial funnel has reached $150 million in total contract value. Management is confident in achieving a $140 million ARR run rate this year and over 30% growth into 2027 and beyond. Investments in deployment capabilities aim to meet revenue targets.
Q:What are the dynamics behind routine imaging volumes being flat while advanced imaging volumes grow?
A:Routine imaging represents 71% of procedures but grows in line with population growth. Advanced imaging, which is 29% of procedures but over 60% of revenue, is growing due to technological advancements and better clinical outcomes.
Q:How are new and acquired centers impacting volumes and integration?
A:New centers in Florida and Indiana contributed $30 million in revenue and $2 million in EBITDA in Q1. Integration is ahead of schedule, and these centers are expected to meet 2026 projections.
Q:What is driving the strength in working capital and record low DSOs?
A:Improvements in revenue cycle management, including better upfront collection of patient responsibilities and querying insurance companies in real-time, have led to strong working capital and low DSOs.
Q:What is the EBITDA contribution from M&A versus same-center performance for 2026 over 2025?
A:About two-thirds of EBITDA growth comes from same-center performance and de novo growth, while slightly less than one-third comes from acquisitions.
Q:What are the key modalities driving EBITDA in Digital Health, and what are the emerging capabilities?
A:Current drivers include clinical AI in mammography and thyroid ultrasound. Emerging capabilities include breast ultrasound, X-ray, and neuro MRI. Management expects this year to be the trough margin year for Digital Health.
Q:What is the false-positive rate in AI for mammography, and how is it being addressed?
A:AI systems are improving through data adaptation and incorporating prior studies. False positives are being reduced, and the AI is approaching or exceeding radiologist accuracy.
Q:What is the significance of the JV with Saint Alphonsus, and how does it serve as a blueprint for future partnerships?
A:The JV integrates all tools for seamless radiology workflow, benefiting radiologists and stakeholders. It aims to connect all imaging providers in the health system, enhancing efficiency and quality.
Q:What is the status of the Gleamer acquisition and its cross-sell opportunities?
A:Training is ongoing, but cross-sell opportunities have already started in the U.S. and internationally. Momentum is building, and the acquisition is expected to contribute significantly.
Q:What are the seasonal factors affecting Q1 EBITDA, and how does it impact the annual cadence?
A:Seasonal factors include payroll taxes, bonus expenses, and lower utilization due to deductible resets and winter weather. EBITDA is expected to increase significantly in subsequent quarters.
Q:What is the reimbursement landscape for AI solutions, and what is the incremental revenue opportunity?
A:Reimbursement opportunities exist for thyroid ultrasound, breast ultrasound, lung nodule detection in CT, and neuro MRI. Adoption and payer coverage are increasing, with significant upside potential.
Q:What is the trajectory for Digital Health profitability and margins?
A:The core business operates at 30-40% EBITDA margins. Recent acquisitions are dilutive but are being integrated. Management expects margins to improve gradually, with a long-term target of 20% by 2028.
Q:What is the internal benefit of AI deployment at RadNet?
A:AI tools are deployed in 70% of RadNet's volumes, improving radiologist productivity and enabling billing for T codes. The full impact is still being realized, with significant opportunities ahead.
Q:What is the updated revenue guidance, and what contributed to the increase?
A:Revenue guidance increased by $30 million due to strong same-center performance and digital health initiatives, not acquisitions.
Q:Is there potential to combine imaging offerings with other treatments for capitated contracts?
A:RadNet currently subcapitates with primary care groups but sees potential opportunities with specialty groups, depending on financial viability.
Q:What is the total number of imaging centers, and what is the target for advanced imaging?
A:RadNet has 440 locations. Advanced imaging is 29% of procedures and 60% of revenue, with potential to exceed 30%.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific EBITDA contribution from M&A versus same-center performance for 2026 over 2025, providing only general proportions. Additionally, the exact impact of AI reimbursement on revenue growth was not quantified, and the potential for combining imaging with other treatments for capitated contracts was discussed in general terms without specific plans or targets.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
ARR subscription
Alphonsus
CMS
Center Segment
DeepHealth
Health Segment
Imaging
Indiana
Northwest Radiology
Regional
Southern California
Southwest Florida
balance
basis point
cash flow
debt
end
fee
health
imaging center
industry
interest
leverage
loss
market
opportunity
outpatient imaging
record
segment
solution
venture
weather condition
winter weather
RDNT Transcript
RadNet, Inc. (RDNT) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary reflects strong financial performance, with a $150 million contract value and a $140 million ARR run rate goal. Advanced imaging is growing, and new centers are ahead of schedule. The JV with Saint Alphonsus and the Gleamer acquisition show strategic growth. Improvements in working capital, low DSOs, and increased revenue guidance further contribute positively. Despite some unclear management responses, the overall sentiment, driven by strong financials, strategic initiatives, and positive guidance, suggests a positive stock price movement.
RadNet, Inc. (RDNT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
RadNet, Inc. (RDNT) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call summary indicates positive financial performance with increased revenue, net income, and EBITDA, despite higher operating expenses. The acquisition of Gleamer aligns with RadNet's strategic focus on AI-driven radiology, potentially boosting future growth. Risks like integration challenges and reimbursement issues were noted, but the raised guidance for 2025 and Medicare reimbursement uplift for 2026 offset these concerns. The lack of shareholder return programs is neutral, but the strategic investments and strong financial metrics suggest a positive stock price movement.
RadNet, Inc. (RDNT) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
Neutral1-14
RDNT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
